Crispr Therapeutics AG vs Lockheed Martin Corporation — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while Lockheed Martin Corporation trades at $596 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 26.4× Crispr Therapeutics AG's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LMT | |
|---|---|---|
Market Cap | $5.23B | $137.96B |
Sector | Health | Industrials |
52-Week High | $76.78 | $676.70 |
52-Week Low | $44.34 | $431.56 |
Enterprise Value | $3.65B | $154.71B |
Dividend Yield | — | 2.31% |
Trailing returns across standard periods
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →